New drug FS-8002 enters human trials for Hard-to-Treat cancers

NCT ID NCT06832982

Recruiting now Disease control Sponsor: Shanghai Pushi Medical Science Co. Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This early-stage trial is testing a new drug called FS-8002, alone or combined with other treatments, in 66 people with advanced solid tumors that have stopped responding to standard care. The main goals are to check safety, find the right dose, and get a first look at whether the drug shrinks tumors. It is a small, first-in-human study, so results will tell us if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FS-8002 injection (a drug), given alone or combined with toripalimab (an immunotherapy) or chemotherapy
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 66 participants, focused mainly on safety and dosing. It is too small and early to know if FS-8002 will be effective or safe for wider use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma glioblastoma hepatocellular carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute,Shandong Cancer Hospital)
RECRUITING

Shandong, Jinan, 250117, China
Fujian Cancer hospital
RECRUITING

Fujian, Fuzhou, 350013, China
Harbin Medical University Cancer Hospital
RECRUITING

Heilongjiang, Harbin, 150081, China
Hebei General Hospital
RECRUITING

Hebei, Shijiazhuang, 050010, China
Hubei Cancer Hospital
RECRUITING

Hubei, Wuhan, 430079, China
Meizhou People's Hospital
RECRUITING

Guangdong, Meizhou, 514031, China
The First Affiliated Hospital of China Medical University
RECRUITING

Shenyang, Shenyang, 110001, China
The First Affiliated Hospital of Zhejiang Medical University
RECRUITING

Zhejiang, Hangzhou, 310003, China
Union Hospital, Tongji Medical College
RECRUITING

Hubei, Wuhan, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.